Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Document and Entity Information

v3.23.1
Document and Entity Information - shares
 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Document Information [Line Items]    
Document Type 20-F  
Amendment Flag false  
Document Period End Date Mar. 31, 2023  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus FY  
Entity Registrant Name Virax Biolabs Group Limited  
Entity Central Index Key 0001885827  
Entity Current Reporting Status Yes  
Entity Voluntary Filers No  
Entity Interactive Data Current Yes  
Current Fiscal Year End Date --03-31  
Entity Filer Category Non-accelerated Filer  
Entity Well-known Seasoned Issuer No  
Entity Common Stock, Shares Outstanding 15,547,089  
Entity Shell Company false  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Securities Act File Number 001-41440  
Entity Incorporation, State or Country Code E9  
Entity Address, Address Line One 20 North Audley Street  
Entity Address, City or Town London  
Entity Address, Postal Zip Code W1K 6LX  
Entity Address, Country GB  
Document Annual Report true  
Document Transition Report false  
Document Shell Company Report false  
Document Registration Statement false  
Document Accounting Standard International Financial Reporting Standards  
ICFR Auditor Attestation Flag false  
Auditor Name BF Borgers CPA PC  
Auditor Firm ID 6906 5041
Auditor Location Lakewood, CO  
Trading Symbol VRAX  
Title of 12(b) Security Ordinary Shares, par value $0.0001 per share  
Security Exchange Name NASDAQ  
Business Contact    
Document Information [Line Items]    
Entity Address, Address Line One 20 North Audley Street  
Entity Address, City or Town London  
Entity Address, Postal Zip Code W1K 6LX  
Entity Address, Country GB  
City Area Code +44 020  
Local Phone Number 7788 7414  
Contact Personnel Name James Foster  
Contact Personnel Email Address info@viraxbiolabs.com